Application of Metabolomics in Alzheimer’s Disease
Progress toward the development of efficacious therapies for Alzheimer’s disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00719/full |
| _version_ | 1811317748357136384 |
|---|---|
| author | Jordan Maximillian Wilkins Eugenia Trushina Eugenia Trushina |
| author_facet | Jordan Maximillian Wilkins Eugenia Trushina Eugenia Trushina |
| author_sort | Jordan Maximillian Wilkins |
| collection | DOAJ |
| description | Progress toward the development of efficacious therapies for Alzheimer’s disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual’s metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below. |
| first_indexed | 2024-04-13T12:13:45Z |
| format | Article |
| id | doaj.art-60ba790110eb41579bf48a8dc4ceafaa |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-13T12:13:45Z |
| publishDate | 2018-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-60ba790110eb41579bf48a8dc4ceafaa2022-12-22T02:47:25ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-01-01810.3389/fneur.2017.00719323079Application of Metabolomics in Alzheimer’s DiseaseJordan Maximillian Wilkins0Eugenia Trushina1Eugenia Trushina2Mitochondrial Neurobiology and Therapeutics Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United StatesMitochondrial Neurobiology and Therapeutics Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United StatesDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United StatesProgress toward the development of efficacious therapies for Alzheimer’s disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual’s metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.http://journal.frontiersin.org/article/10.3389/fneur.2017.00719/fullAlzheimer’s diseasemetabolomicslipidomicsbiomarkersanimal models of Alzheimer’s disease |
| spellingShingle | Jordan Maximillian Wilkins Eugenia Trushina Eugenia Trushina Application of Metabolomics in Alzheimer’s Disease Frontiers in Neurology Alzheimer’s disease metabolomics lipidomics biomarkers animal models of Alzheimer’s disease |
| title | Application of Metabolomics in Alzheimer’s Disease |
| title_full | Application of Metabolomics in Alzheimer’s Disease |
| title_fullStr | Application of Metabolomics in Alzheimer’s Disease |
| title_full_unstemmed | Application of Metabolomics in Alzheimer’s Disease |
| title_short | Application of Metabolomics in Alzheimer’s Disease |
| title_sort | application of metabolomics in alzheimer s disease |
| topic | Alzheimer’s disease metabolomics lipidomics biomarkers animal models of Alzheimer’s disease |
| url | http://journal.frontiersin.org/article/10.3389/fneur.2017.00719/full |
| work_keys_str_mv | AT jordanmaximillianwilkins applicationofmetabolomicsinalzheimersdisease AT eugeniatrushina applicationofmetabolomicsinalzheimersdisease AT eugeniatrushina applicationofmetabolomicsinalzheimersdisease |